Autoreactive-Aβ antibodies promote APP β-secretase processing

Area of Science:

• Neuroscience
• Immunology
• Biochemistry

Background:

• Alzheimer's disease (AD) is linked to amyloid-beta (Aβ) accumulation.
• Naturally occurring autoantibodies against Aβ exist in AD patients, but their functional roles are poorly understood.
• Existing research often focuses on antibody concentration or binding affinity, neglecting functional impacts.

Purpose of the Study:

• To investigate the functional properties of naturally occurring autoantibodies against Aβ in Alzheimer's disease patients.
• To determine if Aβ-targeting autoantibodies influence amyloid precursor protein (APP) processing.
• To explore the potential role of these autoantibodies in the etiology of sporadic AD.

Main Methods:

• Isolation and characterization of Aβ-reactive autoantibodies from AD patients and healthy controls.
• Assaying autoantibody effects on β-secretase activity in cultured cells.
• Utilizing monoclonal antibodies targeting specific Aβ regions (e.g., Aβ(1-17)) to study APP processing.
• Dose-dependent analysis of antibody impact on amyloidogenic APP processing.

Main Results:

• Naturally occurring Aβ-reactive autoantibodies from AD patients, but not controls, enhanced β-secretase activity in cultured cells.
• Monoclonal antibodies targeting the N-terminal region of Aβ, particularly Aβ(1-17), dose-dependently promoted amyloidogenic APP processing.
• Antibody binding to the N-terminus of Aβ correlated with increased Aβ generation via β-secretase activation.

Conclusions:

• Certain autoantibodies targeting Aβ in AD patients can promote Aβ generation by activating β-secretase.
• This autoantibody-driven Aβ production may contribute to the etiology of sporadic Alzheimer's disease.
• Future anti-Aβ immunotherapies must consider potential detrimental effects of N-terminal targeting antibodies on APP processing and Aβ generation.